| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2021―Jul―01 |
Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors |
Kanchan Devkota, Matthieu Schapira, Sumera Perveen, Aliakbar Khalili Yazdi, Fengling Li, Irene Chau, et al. (+14) Pegah Ghiabi, Taraneh Hajian, Peter Loppnau, Albina Bolotokova, Karla J. F. Satchell, Ke Wang, Deyao Li, Jing Liu, David Smil, Minkui Luo, Jian Jin, Paul V. Fish, Peter J. Brown, Masoud Vedadi |
| 2 |
[GO] |
2021―Jun―19 |
Efficiency Improvements and Discovery of New Substrates for a SARS-CoV-2 Main Protease FRET Assay |
Tonko Dražić, Nikos Kühl, Mila M. Leuthold, Mira A. M. Behnam, Christian D. Klein |
| 3 |
[GO] |
2021―Jun―03 |
Application of a High-Content Screening Assay Utilizing Primary Human Lung Fibroblasts to Identify Antifibrotic Drugs for Rapid Repurposing in COVID-19 Patients |
John A. Marwick, Richard J. R. Elliott, James Longden, Ashraff Makda, Nik Hirani, Kevin Dhaliwal, et al. (+2) John C. Dawson, Neil O. Carragher |
| 4 |
[GO] |
2021―Apr―20 |
A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex |
Aliakbar Khalili Yazdi, Fengling Li, Kanchan Devkota, Sumera Perveen, Pegah Ghiabi, Taraneh Hajian, et al. (+2) Albina Bolotokova, Masoud Vedadi |
| 5 |
[GO] |
2021―Apr―17 |
Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry |
Michael D. Scholle, Cheng Liu, Jerome Deval, Zachary A. Gurard-Levin |
| 6 |
[GO] |
2021―Mar―16 |
Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry |
Lesley-Anne Pearson, Charlotte J. Green, De Lin, Alain-Pierre Petit, David W. Gray, Victoria H. Cowling, Euan A. F. Fordyce |
| 7 |
[GO] |
2021―Jan―15 |
A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19 |
Sumera Perveen, Aliakbar Khalili Yazdi, Kanchan Devkota, Fengling Li, Pegah Ghiabi, Taraneh Hajian, et al. (+3) Peter Loppnau, Albina Bolotokova, Masoud Vedadi |
| 8 |
[GO] |
2020―Dec―15 |
Therapeutic and Vaccine Options for COVID-19: Status after 6 Months of the Disease Outbreak |
Dawid Maciorowski, Christian Ogaugwu, Subba Rao Durvasula, Ravi Durvasula, Adinarayana Kunamneni |
| 9 |
[GO] |
2020―Dec―03 |
COMPARE Analysis, a Bioinformatic Approach to Accelerate Drug Repurposing against Covid-19 and Other Emerging Epidemics |
Imad Naasani |
| 10 |
[GO] |
2020―Nov―20 |
Drug Discovery Targeting COVID-19 |
Timothy P. Spicer |
| 11 |
[GO] |
2020―Nov―19 |
CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target |
Tomas Friman, Alexey Chernobrovkin, Daniel Martinez Molina, Laurence Arnold |
| 12 |
[GO] |
2020―Nov―07 |
Saporin, a Polynucleotide-Adenosine Nucleosidase, May Be an Efficacious Therapeutic Agent for SARS-CoV-2 Infection |
Idris Arslan, Hafize Akgul, Murat Kara |
| 13 |
[GO] |
2020―Oct―11 |
High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2 |
Emery Smith, Meredith E. Davis-Gardner, Ruben D. Garcia-Ordonez, Tu-Trinh Nguyen, Mitchell Hull, Emily Chen, et al. (+6) Pierre Baillargeon, Louis Scampavia, Timothy Strutzenberg, Patrick Griffin, Michael Farzan, Timothy P. Spicer |
| 14 |
[GO] |
2020―Sep―28 |
Discovery of Drug-Like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3 |
Rajdeep S. Virdi, Robert V. Bavisotto, Nicholas C. Hopper, Nemanja Vuksanovic, Trevor R. Melkonian, Nicholas R. Silvaggi, David N. Frick |
| 15 |
[GO] |
2020―Sep―18 |
A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19 |
Dawid Maciorowski, Samir Z. El Idrissi, Yash Gupta, Brian J. Medernach, Michael B. Burns, Daniel P. Becker, et al. (+2) Ravi Durvasula, Prakasha Kempaiah |
| 16 |
[GO] |
2020―Aug―17 |
Based on Principles and Insights of COVID-19 Epidemiology, Genome Sequencing, and Pathogenesis: Retrospective Analysis of Sinigrin and ProlixinRX (Fluphenazine) Provides Off-Label Drug Candidates |
Jilan Nazeam, Esraa Z. Mohammed, Mariam Raafat, Mariam Houssein, Asmaa Elkafoury, Dina Hamdy, Lina Jamil |
| 17 |
[GO] |
2020―Jul―21 |
Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status |
Abid H. Banday, Shameem A. Shameem, Sheikh J. Ajaz |
| 18 |
[GO] |
2020―Jul―14 |
RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery |
Wei Zhu, Catherine Z. Chen, Kirill Gorshkov, Miao Xu, Donald C. Lo, Wei Zheng |
| 19 |
[GO] |
2020―Jun―05 |
Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19 |
Mariafrancesca Scalise, Cesare Indiveri |
|
